NTB001

NTB001 is a recombinant human coagulation factor VIII (rFVIII) developed by Nanjing Chia Tai Tianqing Pharmaceutical for the treatment of hemophilia A. Hemophilia A is a genetic bleeding disorder caused by a deficiency or defect in clotting factor VIII, leading to impaired thrombin generation and a high risk of spontaneous or trauma-induced bleeding. NTB001 functions as a replacement therapy, restoring factor VIII activity in the intrinsic pathway of the coagulation cascade. It acts as a cofactor for activated factor IX (FIXa), forming the tenase complex that activates factor X (FX) to factor Xa. This activation is a critical step in the coagulation burst that results in fibrin clot formation. NTB001 is currently in Phase 3 clinical development in China, where it is being evaluated for its efficacy and safety in preventing and treating bleeding episodes in patients with hemophilia A.

Other names

recombinant human coagulation factor VIIIrFVIII